Clinical trial
15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4…
NCT00495729 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00495729 |
|---|---|
| Title | 15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects. |
| Official title | A Single-blind, Randomised, Placebo-controlled, 15 Day Repeated-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SB-649868 and Its Interaction With the CYP3A4 Isoenzyme in Healthy Male Subjects. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Sleep Initiation and Maintenance Disorders |
| Intervention type | Drug |
| Interventions | SB-649868, Placebo, Simvastatin |
| Enrollment | 36 |
| Start date | Apr 18, 2007 |
| Primary completion | Aug 4, 2007 |
| Completion | Aug 4, 2007 |
| First posted | Jul 3, 2007 |
| Last update posted | Aug 8, 2017 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: